Can metformin keep muscles and bones strong as we age?

As people live longer, age-related muscle and bone loss—called sarcopenia and osteoporosis—becomes a major public health problem, robbing billions of mobility and independence. The challenge is that functional decline often starts in middle age, yet we have few proven interventions to catch it early. Metformin, a cheap drug used to treat type 2 diabetes for decades, has shown promise in laboratory aging studies, but whether it can actually preserve musculoskeletal health during early aging has remained unclear.

This study tested metformin in male C57BL/6J mice, starting treatment at middle age (30 weeks, roughly equivalent to 40-50 in humans) and continuing until 53 weeks. The researchers compared three groups: young mice, untreated middle-aged mice, and middle-aged mice given metformin. They measured frailty using standard clinical tests, then dissected muscle, bone, and joint tissues to examine them under a microscope.

The results were encouraging: metformin-treated mice stayed leaner and stronger than untreated middle-aged controls. They scored better on frailty tests and maintained larger muscle fibers with better blood vessel density and less scarring. Bone quality remained robust—trabecular (spongy) architecture and osteoblast (bone-building cell) numbers were preserved. Joints stayed healthier too, with thicker cartilage and intact cartilage cells. Gait (walking pattern) parameters also improved.

However, this is an animal study with significant limitations. Mice are not humans: their metabolism, aging rate, and response to drugs differ substantially. The study was short (23 weeks of treatment) compared to human lifespans, and it only examined male mice, limiting generalizability. The mechanisms by which metformin achieves these effects remain largely unexplored—the paper doesn't explain the biological pathways involved. We also don't know the optimal dose, duration, or whether benefits persist after treatment stops.

This work contributes to growing evidence that metformin has geroprotective potential beyond blood sugar control. It fits a larger narrative in longevity research exploring drug repurposing—finding new uses for existing, cheap medications. However, the leap from mouse to human is substantial. While metformin is safe and widely used, we cannot yet recommend it as an anti-aging treatment; that would require rigorous human trials showing it delays frailty and preserves function in aging adults.

The paper's real value is as a proof-of-concept that early intervention during middle age might preserve musculoskeletal health, and that metformin warrants further investigation in human populations—ideally in randomized controlled trials measuring functional outcomes, not just biomarkers.